MicroRNA News and Research

RSS

In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

EMBL scientists identify two small RNA molecules that ensure red blood cell production

Red blood cells, the delivery men that take oxygen to cells all around the body, have short lives. To keep enough of them in circulation, the human body produces around 2 million of these cells every second - even more in response to challenges like severe blood loss. In a study published today in the Journal of Experimental Medicine, scientists at the European Molecular Biology Laboratory in Monterotondo, Italy, and EMBL's European Bioinformatics Institute in Hinxton, UK, have identified two small RNA molecules which ensure that enough red blood cells are produced efficiently, by fine-tuning a number of different genes involved in this process.

2 Jun 2010

Hitachi Software, OriGene announce co-marketing agreement

Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.

29 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

Exiqon, MultiD Analyses partnership leads to advanced GenEx qPCR data analysis program development

Exiqon A/S, a leader in microRNA analysis products and services, and MultiD Analyses AB, a leader in comprehensive software solutions for qPCR data analysis, today announced a Development and Distribution Agreement incorporating a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform. The agreement allows Exiqon to sell a fully compatible and comprehensive data analysis solution to complete their microRNA qPCR offering.

25 May 2010

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Amsterdam Molecular Therapeutics a world leader in gene therapy, today reported positive preclinical data from a study using an AAV gene therapy product to lower cholesterol.

21 May 2010

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.

20 May 2010

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled, "Discovery of microRNAs and other small RNAs in solid tumors," in the online edition of Nucleic Acid Research.

19 May 2010

Natural molecule in body counters progression of osteoarthritis: Scientists

An international team of scientists from The Scripps Research Institute in California and the National Research Institute for Child Health and Development in Japan has discovered that a natural molecule in the body counters the progression of osteoarthritis. The findings could one day lead to new therapies for some common diseases of aging.

19 May 2010

Exiqon first-quarter revenue increases 29% to record DKK 20.7M

Reported figures are for the full reporting period unless otherwise stated. Figures for the comparable reporting period last year are stated in parenthesis after realized figures. Comparative numbers in the statement of comprehensive income do not include numbers from discontinued operations. Comparative numbers in the statement of financial position include numbers from the discontinued operations.

19 May 2010

WaferGen Biosystems first-quarter revenues increase to $389,785

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.

17 May 2010

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Investigators from around the country came to Sanford-Burnham Medical Research Institute (Sanford-Burnham) on Friday, May 7, to share their knowledge of the burgeoning young field of microRNAs. These small non-coding nucleic acids turn off proteins and have been implicated in viral infection, cancer, cardiovascular disease, HIV and numerous other conditions.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. patent application 11/418,870, including claims related to Sanger hsa-miR-451. miR-451 is used in the Company's miRview™ mets test, which accurately identifies the primary tumor site in patients with metastatic cancer and Cancer of Unknown Primary (CUP).

11 May 2010

Scientists analyze genetic networks of microRNAs in tumors

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships. Researchers are now discovering how biological networks change and are rewired in cancer.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

BioDiscovery signs OEM Agreement with Exiqon

BioDiscovery, Inc., a leader in integrated software solutions for microarray-based research, and Exiqon A/S, a leader in microRNA analysis products and services, announced today an OEM Agreement incorporating BioDiscovery's array analysis and visualization software with Exiqon's arrays.

5 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Scientists introduce a new way of identifying key cancer genes

A new study shows that a family of molecules called microRNA work together in single, well-connected networks to control many important functions in healthy cells, but that in cancer cells the networks are rewired and fragmented.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

MicroRNA News and Research

Further Reading

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

EMBL scientists identify two small RNA molecules that ensure red blood cell production

Hitachi Software, OriGene announce co-marketing agreement

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Exiqon, MultiD Analyses partnership leads to advanced GenEx qPCR data analysis program development

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Natural molecule in body counters progression of osteoarthritis: Scientists

Exiqon first-quarter revenue increases 29% to record DKK 20.7M

WaferGen Biosystems first-quarter revenues increase to $389,785

Sanford-Burnham Scientific Symposium provides wealth of information on microRNAs, RNAi

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Rosetta Genomics announces USPTO notice of allowance for Sanger hsa-miR-451

Scientists analyze genetic networks of microRNAs in tumors

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

BioDiscovery signs OEM Agreement with Exiqon

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Scientists introduce a new way of identifying key cancer genes

QIAGEN reports 20% revenue growth in first quarter 2010

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics